PCM
EIGR

Penserra Capital Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Penserra Capital Management’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-26
Closed -$5K – 1595
2021
Q3 		$5K Hold
26
– – ﹤0.01% 1412
2021
Q2 		$6K Buy
26
+1
+4% +$250 ﹤0.01% 1312
2021
Q1 		$6K Hold
25
– – ﹤0.01% 1082
2020
Q4 		$9K Buy
25
+17
+213% +$4.88K ﹤0.01% 938
2020
Q3 		$2K Buy
+8
New +$2.49K ﹤0.01% 912

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Penserra Capital Management's EIGR Position: Q4 2021 in Review

Penserra Capital Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2021, closing a stake of 26 shares — an estimated $5K sold.

Penserra Capital Management first reported a position in EIGR in Q3 2020 and held it in 5 quarters. The position peaked at $9K in Q4 2020. 85 funds tracked by Wall St. Rank hold EIGR as of Q4 2021.

  • Penserra Capital Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 26 Eiger BioPharmaceuticals, Inc. shares in Q4 2021, an estimated $5K.
  • Penserra Capital Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q3 2020 and held it in 5 quarters.
  • Penserra Capital Management's Eiger BioPharmaceuticals, Inc. position peaked at $9K in Q4 2020.
  • 85 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.